Introduction
Cytotoxic T lymphocytes (CTLs) play a crucial role in host immune responses to cancer. Effective adoptive cancer immunotherapy with tumor-sensitized CTLs has been well documented in animal models, where transfer of such tumor-specific T cells into mice bearing tumors resulted in tumor eradication, [1] [2] [3] but not autoimmunity. 4 Recently, it has further been reported that adoptive transfer of cytotoxic T type 1 cells can cure 70% palpable tumors. 5 More recently, Becker et al. 6 have shown that Tc cells enriched through an interferon (IFN)-g-capture method displayed enhanced tumor-specific cytotoxicity and the adoptive therapy with these T cells cured 3/5 mice bearing 3-day tumors. In most of these animal models, T-cell adoptive therapy is all limited in treatment of earlystage tumors (e.g., 3-day or palpable tumors or 3-10-day early lung metastases), but not large tumors. However, it is the well-established tumors in animal models that mimic the clinical patients with existing tumor burdens. Therefore, new strategies with improved therapeutic efficiency are expected.
IL-10 has been identified as a key immunomodulatory cytokine capable of mediating immunosuppressive effects in immune systems. It inhibits cytokine production and proliferation of CD4 þ T cells 7 and reduces expression of major histocompetibility complex (MHC) class II, intracellular adhesion molecule (ICAM)-1 and CD80 on dendritic cells (DCs), resulting in induction of T-cell anergy 8, 9 or regulatory T (Tr) cells that suppress antigen-specific T-cell responses 10, 11 IL-10 was found in many human tumors 12, 13 It has been demonstrated that tumor-induced IL-10 (i) blocks tumor-specific helper T type 1 (Th1) responses, 14 (ii) inhibits tumor-specific CD8 þ CTL cytotoxicity 15 and (iii) supports the tumor growth. 16 in animal tumor models. Therefore, T-cell suppression derived from tumor-secreted IL-10 becomes one of the major barriers to T-cell immunotherapy of tumors. Clinically, the detectible serum IL-10 in cancer patients becomes a negative indicator for clinical outcome 17, 18 TNF-a is a multifunctional cytokine with a broad spectrum of activities. It activates IL-2R/IFN-g expression and cytotoxicity of T cells, 19 and stimulates T-cell proliferation and activation 20 through activation of nuclear factor-kappa B (NF-kB) involving multiple cytokine activation. 21, 22 Recently it has been shown that TNF-a can provide the costimulatory survival signals for CD8 þ T cells in the absence of B7-CD28 and IL-2 costimulatory pathways. 23 In addition to T-cell activation, TNF-a can also stimulate the DC maturation 24 and reduce/counteract IL-10-mediated DC inhibition. 25 We hypothesized that TNF-a-gene engineered CD8 þ
T cells may directly counteract IL-10-induced T-cell suppression and improve CD8
þ T-cell therapy of solid tumors. In this study, we constructed an expression vector pcDNAIL-10 expressing immunosuppressive IL-10 and a recombinant fiber-modified adenovirus ( MF AdVTNF) expressing the human TNF-a. By using the above reagents, we then generated the OVA-specific TNF-a gene-engineered CD8 þ T (T TNF ) cells with MF AdVTNF and the IL-10 gene-transfected OVA-expressing melanoma cell line B16 OVA/ILÀ10 with pcDNAIL-10. We further investigated the potential therapeutic effect of engineered CD8 þ T TNF cells in treatment of IL-10-secreting and OVA-expressing B16 OVA/ILÀ10 solid tumors and lung micrometastasis.
Materials and methods
Antibodies, cytokines, adenoviruses, cell lines and animals Biotin-conjugated anti-mouse MHC class I (H-2K b ), CD8, CD25, CD45.1, CD45.2, CD69, Va2Vb5 þ T-cell receptor (TCR) and Fas ligand (FasL) antibodies (Abs), the R-phycoerythrin (PE)-conjugated anti-mouse IL-4, IL-10, IFN-g and perforin Abs and anti-human TNF-a (hTNF-a) Ab were all obtained from Pharmingen Inc. (Mississauga, Ontario, Canada). Fluorescein isothiocyanate (FITC) or energy-coupled dye (ECD)-conjugated avidin or anti-mouse immunoglobulin G (IgG) Ab was obtained from Bio/Can Scientific (Mississauga, Ontario, Canada). PE-labeled H-2K b /OVA 257-264 tetramer and FITC-labeled rat anti-mouse CD8 Ab were obtained from Beckman Coulter (San Diego, CA). The recombinant mouse granulocyte monocyte-colony stimulating factor (GM-CSF), IL-2 and IL-4 were purchased from R&D Systems (Minneapolis, MN). The chicken egg ovalbumin (OVA) protein, concanamycin A (CMA) and emetin were obtained from SIGMA (St Louis, MO). The mouse anti-OVA Ab was purified by using Protein G affinity column from antisera of the mice immunized with OVA emulsified in adjuvant. The recombinant adenovirus (AdV) AdVTNF expressing the human TNF-a was previously constructed using the adenoviral vector pLpATNF in our laboratory. 26 The highly lung metastatic melanoma cell line BL6-10 (B16) and its derivative OVA-transfected cell line BL6-10OVA (B16 OVA ) were generated in our laboratory. 27 The mouse thymoma cell line EL4 and its derivative OVA-transfected cell line EG7 were obtained from American Type Culture Collection (ATCC, Rockville, MD). Both B16 OVA/ILÀ10 and EG7 tumor cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and G418 (0.5 mg/ml). The human embryonic kidney cell line 293 containing adenovirus (AdV) 5 E1 region was obtained from ATCC. The OVA-specific TCR transgenic OT I mice having a transgenic Va2Vb5 TCR specific for OVA 257-264 epitope in context of H-2K b ,
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C57BL/6(TNF-a À/À ) mice with TNF-a gene knockout (KO), C57BL/6 (B6, CD45.2 þ ) and C57BL/6.1 (B6.1, CD45.1 þ ) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Homozygous OT I (TNF-a À/À ) mice were generated by backcrossing female C57BL/ 6(TNF-a À/À ) mice onto the male OT I background for two generations. Animal care was in accord with the guidelines of the University of Saskatchewan.
Construction of pcDNA/IL-10 expression vector Total RNA was extracted from mouse splenocytes using RNeasy Mini Kit (Qiagen, Mississauga, Ontario, Canada). A 1 kb cDNA fragment coding for the full openreading frame of mouse IL-10 gene was cloned by reverse transcription-polymerase chain reaction (RT-PCR) from a cDNA library derived from the splenocyte RNA using PFU polymerase. Two primers specific for the mouse IL-10 gene were used, namely the sense primer (5 0 -atgag acttc tcctc ctg-3 0 ) and the anti-sense primer (5 0 -ttacc cagtc agggt tactg-3 0 ). The cloned cDNA fragment was ligated into the pCR2.1 (Invitrogene, Carlsbad, CA) to form the pCR2.1IL-10 vector. The IL-10 sequence was verified by dideoxy nucleotide sequencing method. The cDNA fragment of IL-10 (XbaI/HindIII) from the pCR2.1IL-10 vector was further ligated into pcDNA vector (Invitrogene) containing the hygromycin-resistant gene to form the expression vector pcDNAIL-10.
Engineering B16 OVA/ILÀ10 tumor cells to secrete IL-10 Twenty million B16 OVA tumor cells were resuspended in 0.7 ml phosphate-buffered saline (PBS) and mixed with another 0.3 ml PBS containing 10 mg pcDNAIL-10 or the control pcDNA DNA. Tumor cells were transfected with the above vector DNA using a Bio-Rad gene pulser (Bio-Rad Laboratories, Mississauga, Ontario, Canada) with parameters of 250 V and 125 mFD capacitance. The transfected B16 OVA/ILÀ10 or the control B16 OVA/control tumor cells by using pcDNAIL-10 and the control pcDNA vectors were selected for growth in the medium containing G418 (0.5 mg/ml)/hygromycin (4 mg/ml), respectively, and then maintained in the medium containing G418 (0.5 mg/ml)/hygromycin (0.5 mg/ml).
Construction of fibre-modified FMAdVTNF expressing TNF-a
The recombinant fiber-modified adenovirus MF AdVTNF expressing the transgene human TNF-a 26 was constructed using the AdEasy system (Stratagene, La Jolla, CA) as previously described. 29 The fiber gene was modified by insertion of RGD motif into the viral H1 loop similarly to the method described by Liu et al. 30 Briefly, the pAdEasy-1 vector was digested with BamHI, resulting in 21.7 and 11.7-kb DNA fragments. The 11.7-kb fragment was gel purified and inserted into pCRBlunt (Invitrogen, Carlsbad, CA) to form a pCR11.7 vector. The pCR11.7 vector was digested with EcoRI, resulting in 9.3 and 5.6-kb DNA fragments. The 9.3-kb fragment containing the pCRBlunt backbone underwent self-ligation, forming a pCR9.3 vector. PCR amplification was used to replace the DNA sequence within the StuI-AflII sites of the fiber knob domain in pCR9.3 vector. In PCR, the sense primer 1 (5 0 -caaca aaggc cttta cttgt ttaca gcttc a-3 0 ) and the antisense primer 2 (5 0 -tgaca tagag tactg gttta gtttt gtctc cgttt aag-3 0 ) were used to amplify a 680-bp P1 þ P2 fragment (nucleotides 31 950-32 630 of the AdV5 genome), whereas the sense primer 3 (5 0 -actaa accag tactc tatgt cattt tcatg ggact ggt-3 0 ) and the antisense primer 4 (5 0 -tggac agcga catga acttt aagtg agctg-3 0 ) were used to amplify a 435-bp P3 þ P4 fragment (nucleotides 32 690-33 125 of the AdV5 genome). The P1 þ P2 and P3 þ P4 fragments were gel purified, mixed, and joined by PCR using P1 and P4, resulting in a 1.1-kb fragment. This fragment contains part of the knob sequence of AdV5 with AflII (nucleotide 31 950) and StuI (nucleotide 33 125) sites. A deletion was created from 32 631 to 32 689 by removing amino-acid residue VTLTI TLNGT QETGD TTPSA, and incorporating a single mutation from T to A to create a ScaI site in the H1 loop. Plasmid pCR9.3(AS) was constructed by inserting the 1.1-kb PCR fragment into the pCR9.3 vector. A duplex was formed by annealing two complimentary oligonucleotides (5 0 -aacac taacc attac actaa acggt acaca ggaaa cagga gacac aactt gcgac tgtag aggag actgc ttttg tccaa gtgca t-3 0 and 5 0 -atgca cttgg acaaa agcag tctcc tctac agtcg caagt tgtgt ctcct gtttc ctgtg taccg tttag tgtaa tggtt agtgt t-3 0 ). This 86-bp duplex was cloned into ScaI-digested pCR9.3(AS), forming the pCR9.3(RGD) plasmid which contains the AdV5 complete sequence (nucleotides 31 950-33 125) and an additional RGD-4C sequence (CDCRGDCFC) in the HI loop (between nucleotides 32 679 and 32 680). The previously generated 5.6-kb fragment was inserted into EcoRI-digested pCR9.3(RGD) to form pCR11.7(RGD). The resulting 11.7-kb BamHI band from pCR11.7(RGD) was ligated into the previous 21.7-kb BamHI fragment of pAdEasy-1, resulting in pAdEasy(RGD). This 33.4-kb plasmid contains the pAdEasy-1 sequence plus an additional RGD-4C sequence in the H1 loop. All of the insert orientations within the vectors were determined by dideoxy nucleotide sequencing method and restriction enzyme-digestion analysis. The shuttle vectors pLpATNF with the human TNF-a gene and the control pLpA without any transgene were used. 26 The PmeI-digested shuttle vectors were then cotransformed into BJ5183 Escherichia coli cells already containing the backbone vector pAdEasy(RGD) for increased efficiency of homologous recombination 31, 32 to form the recombinant vectors pAd(RGD)TNF ( Figure 1 ) and pAd(RGD), respectively. The recombinant pAd(RGD)TNF and pAd(RGD) vectors were linealized by PacI digestion, and then transfected into 293 cells using Lipofectamine (Gibco/BRL, Burlington, Ontario, Canada) to generate the fibermodified adenoviruses MF AdVTNF with the transgene human TNF-a expression ( Figure 1 ) and the fiber-modified control MF AdV without any transgene expression. The fiber-modified MF AdVGFP expressing the marker gene GFP was obtained from Dr Zheng, NIH, Bethesda, MD. All recombinant adenoviruses were amplified in 293 cells, Figure 1 Schematic representation of recombinant adenoviruses. The recombinant adenoviruses AdVTNF and MF AdVTNF were constructed using the adenoviral vectors pLpATNF 26 and pAd(RGD)TNF, respectively. The RGD (bold) motif was incorporated into the H1 loop of the fiber. For detail, see text. CMV, cytomegalovirus promoter; poly A, bovine growth hormone polyadenylation signal; LITR, left inverted terminal repeat; RITR, right inverted terminal repeat.
TNF-a-gene engineered CD8
þ T-cell therapy Z Ye et al purified by a series of cesium chloride ultracentrifugation gradients, and stored at À801C until use.
Preparation of bone marrow-derived DCs
The preparation of bone marrow (BM)-derived DCs was previously described. 27 Briefly, BM cells prepared from femora and tibiae of normal C57BL/6 (H-2K b ) mice were depleted of red blood cells with 0.84% ammonium chloride and plated in DC culture medium (DMEM plus 10% FCS, GM-CSF (20 ng/ml) and IL-4 (20 ng/ml)). On day 3, the nonadherent granulocytes, and T and B cells were gently removed, and fresh media were added. After 2 days, the loosely adherent proliferating DC aggregates were dislodged and replated. On day 6, the nonadherent cells were harvested. The DCs generated in this manner displayed (i) typical morphologic features of dendritic cells (i.e., numerous dendritic processes) and (ii) expression of MHC class I (H-2K b ) and II (Ia b ) antigens, costimulatory molecules (CD40, CD80 and CD86) and adhesion molecules (ICAM-1, CD11b and CD11c) (data not shown).
Preparation of OVA-specific CD8
þ T cells Naı¨ve OVA-specific CD8 þ T cells were isolated from the spleens and lymph nodes of OT I or OT I(TNF-a À/À ) TCR-transgenic mice, enriched by passage through nylon wool columns (C&A Scientific, Manassa, VA), and then fractionated by negative selection using anti-mouse CD4 (L3T4) paramagnetic beads (DYNAL Inc., Lake Success, NY) according to the manufacturer's protocols. BMderived DCs were loaded with OVA protein (0.3 mg/ml) at 371C for overnight, and referred to as DC OVA . The above purified naı¨ve CD8 þ T cells from OT I mice (3 Â 10 5 cells/ml) were stimulated with irradiated (4000 rad) DC OVA (2 Â 10 5 cells/ml) in presence of IL-2 (20 U/ml) for 3 days, and purified using Ficoll-Paque (Sigma, St Louis, MO) density gradient centrifugation and then CD8 microbeads (Miltenyi Biotec, Auburn, CA). 33 DC OVA -activated CD8 þ T cells derived from OT I and OT I(TNF-a À/À ) mice were referred to as CD8 þ T and T(TNF-a À/À ) cells, respectively. The phenotypes and cytokine profiles of CD8 þ T(TNF-a À/À ) cells are similar to CD8 þ T cells, except for the TNF-a deficiency (data not shown).
Engineering CD8
þ T TNF cells with FMAdVTNF To assess the optimal multiplicity of infection (MOI) for maximal transgene expression, CD8 þ T cells were transfected with AdVGFP at various MOIs for 1 day and examined by fluorescence microscopy. The number of transfected CD8
þ T cells expressing GFP at various MOIs was calculated. The above DC OVA -activated CD8 þ T cells were further incubated with the fiber-modified FMAdVTNF-a and the control FMAdV at MOI of 100. 34 Following the viral adsorption for 1 h at 371, the T-cell culture medium was replaced with DMEM/10% FCS/IL-2 (10 U/ml), and the T cells were incubated for another 24 h at 371. CD8
þ T cells transfected with FMAdVTNF and the control FMAdV were referred to as CD8 þ T TNF and CD8 þ Tcontrol cells, respectively.
RT-PCR analysis of cytokine expression
Total RNA was obtained from the transfected B16 OVA/ILÀ10 or the control B16 OVA cells, as well as the DC OVA -activated CD8 þ T cells, the engineered CD8 þ T TNF cells and the control CD8 þ T control cells. The firststrand cDNA synthesis for RT-PCR was performed with 5 mg of RNA using a commercial kit (Stratagene, La Jolla, CA), following the manufacturer's instructions. The PCR primers included the sense primer (5 0 atgag acttc tcctc ctg-3 0 ) and the antisense primer (5 0 -ttacc cagtc agggt tactg-3 0 ) for the mouse IL-10, and the sense primer (5 0 -atgag acttc tcctc ctg-3 0 ) and the antisense primer (5 0 -ttacc cagtc agggt tactg-3 0 ) for the human TNF-a. In addition, another one set of primers was also used, including the sense primer (5 0 -caggt tgtct cctgc gactt-3 0 ) and the antisense primer (5 0 -cttgc tcagt gtcct tgctg-3 0 ) for the control gene glyceraldehyde phosphate dehydrogenase (GAPDH). The PCR conditions comprised one cycle at 941C (5 min), 541C (1 min) and 721C (1 min), and 25 cycles at 941C (1 min), 551C (1 min) and 721C (1 min). All PCR reaction products were resolved on 1% agarose gels with ethidium bromide staining. 
þ T cells, which were further cultured in medium containing recombinant IL-2 (10 U/ml) and recombinant human TNF-a (10 ng/ml) for 1 day and referred to as 'T þ rTNF' cells, were stained with a panel of biotin-conjugated Abs (2 mg/ml) for 1 h on ice, washed with PBS, and then incubated for 1 h on ice with FITC-conjugated avidin. After another three washes with PBS, the above cells were analyzed by flow cytometry. To examine the intracellular expression of cytokines, the above cells were processed using a commercial kit (Cytofix/CytoPerm Plus with GolgiPlug; Pharmingen, Inc.), and stained with PE-conjugated anti-IL-4, -IL-10, -IFN-g, -hTNF-a or -perforin Abs, according to the manufacturers' protocols. 33 Cytokine secretion by tumor or T cells in the supernatants from their 24 h cell culture in vitro was assessed using the commercial enzyme-linked immunosorbent assay (ELISA) kits (Endogen, Woburn, MA). To examine IL-10 secretion by B16 OVA/ILÀ10 tumors in vivo, the protein extracts were prepared by homogenization of tumor tissues in 125 mM Tris, 0.05% sodium dodecyl sulfate (SDS), 10% b-mercaptoethanol, followed by centrifugation at 1000 g for 5 min. Cytokine secretion by tumors in vivo in the supernatants were also assessed using enzyme-linked immunosorbent assay (ELISA) kits. The results were normalized to the recombinant cytokine standard curves.
Tumor cell growth in vitro and in vivo
To assess tumor cell growth in vitro, the engineered B16 OVA/ILÀ10 and the original B16 OVA tumor cells (0.2 Â 10 6 cells) were plated in each of the small flasks containing 5 ml of culture medium, and then counted
viability of the cells using trypin blue exclusion method daily. To assess tumor cell growth in vivo, the above tumor cells (0.5 Â 10 6 cells per mouse) were s.c. inoculated into the right thighs of C57BL/6 mice, and tumor growth was monitored daily using a caliper.
T-cell cytotoxicity assay
The engineered CD8 þ T TNF and the control CD8 4 labeled target cells per triplicate well were mixed with effector cells at various E:T cell ratios, and then incubated for 6 h. For testing the killing mechanism, the effector cells were pre-incubated with CMA (1 mM) and emetin (5 mM) for 2 h to prevent perforin (CMA)-or Fas/FasL interaction (emetin)-mediated cytotoxicity. 34 The percentage of specific lysis was calculated as: 100 Â ((experimental count per minute (cpm)Àspontaneous cpm)/(maximal cpmÀspontaneous cpm)). Spontaneous cpm release in the absence of E cells was o10% of specific lysis. The maximal cpm release was determined by lysis of T cells with 0.25% Triton X-100.
Adoptive CD8
þ T-cell immunotherapy models For treatment of lung micrometastasis, C57BL/6 mice (10 per group) were i.v. injected with B16 and B16 OVA/ILÀ10 tumor cells (0.5 Â 10 6 cells per mouse), respectively. At 12 days after tumor cell injection, mice had lung micrometastasis. 5 These mice were then treated with i.v. injection of the engineered CD8 þ T TNF and the control CD8 þ T control or 'T þ rTNF' cells (2 Â 10 6 cells per mouse). The mice were killed 4 weeks after tumor cell injection, and the lung metastatic tumor colonies were counted in a blind fashion. 27 Metastases on freshly isolated lungs appeared as discrete black-pigmented foci that were easily distinguishable from normal lung tissues and confirmed by histological examination. Metastatic foci too numerous to count were assigned an arbitrary value of 4100. For treatment of established solid tumors, C57BL/6 mice (10 per group) were s.c. inoculated with 0.5 Â 10 6 B16 OVA/ILÀ10 tumor cells in their thighs. At 10 days after tumor cell inoculation, tumor grew to B5 mm in diameter. The tumor-bearing mice were then i.v. injected with the engineered CD8 þ T TNF and the control CD8 þ T control cells (5 Â 10 6 cells per mouse), respectively. The tumor growth was then monitored daily using a caliper. To assess long-term antitumor immunity, C57BL/ 6 mice (12 per group) were i. 
6 cells per mouse) derived from OT I(TNF-a À/À ) mice. A tetramer staining assay was performed to examine the presence of OVA-specific CD8 þ T cells in the mouse peripheral blood at 5 days and once a week for 3 months after the adoptive transfer as described above.
Results

Transfected B16 OVA/ILÀ10 cells express the transgene IL-10
We first cloned the mouse IL-10 gene and constructed an expression vector pcDNAIL-10 expressing the mouse IL-10. We then transfected the mouse melanoma cell line B16 OVA expressing OVA with the expression vector pcDNAIL-10 and the control vector pcDNA to generate the transfected B16 OVA/ILÀ10 and the control B16 OVA/control tumor cell lines. To examine the IL-10 transgene expression, RNA extracted from the transfected B16 OVA/ILÀ10 , the control B16 OVA/control and the original B16 OVA tumor cells was subjected to RT-PCR analysis. As shown in Figure 2a, (Figure 2b) . We then performed in vitro and in vivo growth rate assays. The transfected B16 OVA/ILÀ10 tumor cells displayed a similar in vitro and in vivo growth rate compared to the original B16 OVA tumor cells (Figure 2c ). The IL-10 secretion by B16 OVA/ILÀ10 tumors in vivo was estimated to be 16 mg/g of tumor tissues as determined by ELISA.
Engineered CD8
þ T TNF cells express the transgene human TNF-a The OVA-specific CD8 þ T cells were generated by incubation of naı¨ve CD8 þ T cells from OT I transgenic mice with OVA-pulsed DC OVA . To assess the optimal MOI for maximal transgene expression, CD8
þ T cells were transfected with AdVGFP at various MOIs and examined by fluorescence microscopy. The number of transfected CD8
þ T cells expressing GFP increased with increased MOI. The maximal transfection with 85% GFP-positive CD8 þ T cells was obtained at MOIs of X100. Therefore, MOI of 100 was selected for transfection of CD8 þ T cells in this study. These CD8 þ T cells were further transfected with the fiber-modified MF AdVTNF and the control MF AdV at MOI of 100, and termed as the engineered CD8
þ T TNF and the control CD8 þ T control cells. As shown in Figure 3a , these CD8 þ T cells all expressed IL-2 receptor (CD25), active T-cell marker (CD69) and Va2Vb5 þ TCR, indicating that they are active OVA-specific CD8 þ T cells. These active CD8 þ T cells also expressed intracellular mouse IFN-g, but not IL-4, indicating that they are type 1 CD8 þ T cells. In addition, CD8
þ T control cells did not express intracellular human TNF-a, whereas CD8 þ T TNF cells did express the transgene-coded human TNF-a. To quantify the cytokine secretion, we performed ELISA analysis. These CD8 þ T cells secreted the mouse IFN-g (B0.6 ng/ml/10 6 cells/24 h) and the mouse TNF-a (0.4 ng/ ml/10 6 cells/24 h), but did not secrete any mouse IL-4 in their supernatants. In addition, they also displayed cell surface FasL and intracellular perforin. The phenotypes of CD8 þ 'T þ rTNF' cells cultured in medium containing recombinant human TNF-a were similar to the control CD8 þ T control cells cultured in medium without recombinant TNF-a (data not shown). The phenotypes of the engineered CD8
þ T TNF cells were also similar to those of the control CD8 þ T control cells, except for an increased expression of perforin in engineered CD8
þ T TNF cells. To assess the transgene expression, we performed RT-PCR analysis. As shown in Figure 3b , the human TNF-a expression was only found in the engineered CD8 þ T TNF cells, but not in the control CD8 þ T control and the untransfected CD8 þ T cells. To quantify transgene (human TNF-a) secretion of the engineered T TNF cells, we also performed ELISA assay. Human TNF-a secretion of the engineered T TNF cells was estimated to be 4.3 ng/ml per 10 6 cells per24 h, which is more than 10-fold than the secreted mouse TNF-a. Interestingly, the human TNF-a secretion of the engineered T cells generated by using the original AdVTNF without fiber modification 26 was estimated to be only B0.8 ng/ml/10 6 per cells per 24 h, more than fivefold less than that (4.3 ng/ml/10 6 cells/24 h) TNF-a-gene engineered CD8 þ T-cell therapy Z Ye et al of the engineered CD8 þ T TNF cells generated by using fiber-modified MF AdVTNF, indicating that the adenoviral fiber modification with RGD motif insertion into the viral knob's H1 loop greatly enhances AdV infection to CD8 þ T cells. The cytokine profiles of the engineered CD8 þ T TNF cells are also similar to those of the control CD8 þ T control cells and the untransfected CD8 þ T cells (data not shown), except that the later two did not express the human TNF-a.
þ T TNF cells display stronger cytotoxicity to OVA-expressing B16 OVA tumor cells in vitro To assess the T cell cytotoxicity, we performed chromium release assay. As shown in Figure 4a , the engineered CD8 þ T TNF cells exhibited stronger cytotoxicity (75% specific killing at an E:T cell ratio of 50) for OVAexpressing B16 OVA/ILÀ10 tumor cells than the control CD8 þ T control cells (48% specific killing at an E:T cell ratio of 50) (Po0.05). However, the above killing activities were not for the parental B16 tumor cells without OVA expression, indicating that the killing activity is OVA specific. To study the killing mechanism, concanamycin A (CMA) and emetin were used to inhibit the perforin-and Fas/FasL interaction-mediated cytotoxicity, respectively. Our data showed that both CMA and emetin demonstrated a dose-dependent inhibition of the engineered CD8 þ T TNF (Figure 4b ) and the control CD8 þ T control (data not shown)-cell cytotoxicity. The treatment of CMA at 1 mM induced almost a complete inhibition (94%) of T TNF -cell cytotoxicity, whereas the treatment of emetin even at 5 mM resulted in a maximal inhibition (12%), indicating that the perforin-mediated pathway plays a major role in CTL cytotoxicity.
IL-10-secreting tumors are more resistant to CD8
þ T-cell therapy To treat lung metastasis, the control CD8 þ T control cells were i.v. transferred into the mice bearing 12-day lung micrometastasis. As shown in Experiment I of Table 1 , the control CD8 þ T control cells eradicated B16 OVA lung metastasis without IL-10 secreting in all 10/10 mice, but Expression of the transgene human TNF-a. RNA was extracted from T cells. The first-strand cDNA was synthesized from RNA using the reverse transcriptase, and the PCRs were conducted using a set of primers for the human TNF-a and the control 'house-keeping' gene GAPDH, respectively. One representative experiment of two is displayed.
TNF-a-gene engineered CD8
þ T-cell therapy Z Ye et al eliminated IL-10-secreting B16 OVA/ILÀ10 lung metastasis in only 2/10 mice, indicating that immunosuppressive IL-10-secreting tumors are more resistant to CD8 þ T-cell therapy. To assess the therapeutic effect on solid tumors, the control CD8 þ T control cells were i.v. transferred into the mice bearing 10-day solid tumors (B5 mm in diameter). All mice died within 16 days subsequent to tumor cell challenge. In mice bearing B16 OVA tumors, 40% (4/10) of the mice treated with the control CD8 þ T control cells were free of tumors (Figure 5a ). The original tumors (B5 mm in diameter) in these mice with tumor regression gradually disappeared starting at day 2 after CD8 þ T-cell transfer. In mice bearing B16 OVA/ILÀ10 tumors, however, all (10/10) mice with treatment of the control CD8 þ T control cells died within 24 days after tumor cell challenge (Figure 5b ), confirming that IL-10-secreting tumors are more resistant to CD8 þ T-cell therapy.
Engineered CD8
þ T TNF cells have enhanced therapeutic effect on IL-10-secreting lung metastasis and solid tumors To assess the therapeutic efficacy on lung metastasis, the engineered CD8 þ T TNF cells were i.v. transferred into the mice bearing 12-day lung micrometastasis. As shown in Table 1 , DC OVA -activated CD8 þ T (T control ) and DC OVAactivated CD8 þ T (T þ rTNF) cells with further culturing in the medium containing recombinant human TNF-a did not efficiently cure IL-10-secreting B16 OVA/ILÀ10 lung metastasis because 80-90% of mice in these two groups of mice still died after the treatment. However, the engineered CD8 þ T TNFcell-treated group was also significantly delayed compared to the group of mice treated with the control CD8 þ T control cells (Po0.05).
Engineered CD8 þ T TNF cells have prolonged survival in vivo
The successful cancer T-cell therapy is critically dependent upon duration of in vivo persistence of the transferred CD8 þ T cells. 37 To assess in vivo survival of the engineered CD8
þ T TNF cells, we performed a kinetic study. In the kinetic study, we measured the amount of OVA-specific CD8 þ T cells in the peripheral blood of B6.1 mice (CD45.1 þ ) with i.v. transfer of CD8 þ T cells derived from OT I mice (CD45.2 þ ) using PE-labeled H-2K b /OVA 257-264 tetramer staining at different time points after adoptive transfer. As shown in Figure 6a and b, the number of totally detected OVA-specific CD8 þ T cells in peripheral blood of the mice with the engineered CD8 þ T TNF and the control CD8 þ T control cell transfer accounted for 18 and 12% of the total CD8 
TNF-a-gene engineered CD8
þ T-cell therapy Z Ye et al T-cell population, respectively, at day 5 after adoptive transfer. The numbers then gradually dropped to 14 and 9.3% at day 12, and 1.8 and 1.2% at day 30 subsequent to adoptive transfer, and then stably maintained for at least 3 months, indicating that the engineered CD8 þ T TNF cells have prolonged survival in vivo, compared with the control CD8 þ T control cells. Since these long-term survival CD8 þ T cells should be considered to be memory T (Tm) cells with the capacity of expansion upon antigen stimulation, 38 we boosted these mice with OVA-pulsed DC OVA 3 months after adoptive transfer, and then measured the number of OVA-specific CD8 þ T cells in the peripheral blood 4 days after the boost. As shown in Figure 6c , the expanded OVA-specific CD8 þ T cells accounted for 22 and 34% of the total CD8 þ T-cell population in the mice with previous transfer of CD8 þ T control and T TNF cells, respectively. To examine the origin of these expanded OVA-specific CD8 þ T cells, we þ T TNF -cell-treated mouse group* is significantly longer than that of the T control -cell-treated group (Log rank test, Po0.05). One representative experiment of two is shown.
þ T-cell therapy Z Ye et al performed ECD-CD45.1 or ECD-CD45.2 staining. The majority (B80%) of the expanded OVA-specific CD8 þ T cells were CD45.2 positive, indicating that they are derived from the originally transferred donor CD8 þ T cells. Interestingly, we also found that around 20% of the expanded OVA-specific CD8 þ T cells were CD45.1-positive, indicating that they are derived from the host.
Adoptive transfer of engineered CD8
þ T TNF cells induces long-term antitumor immunity We next investigated the potential long-term immunity derived from adoptive transfer of CD8 þ T TNF cells. The immunized mice with CD8 þ T TNF and T controlcell transfer were challenged with s.c. injection of B16 OVA/ILÀ10 tumor cells 3 months after adoptive transfer. As shown in Figure 6d , transfer of both the engineered CD8 þ T TNF and the control CD8 þ T control cells completely protected 12/12 (100%) mice from a challenge of 0.3 Â 10 6 B16 OVA/ILÀ10 tumor cells. However, when challenging the mice with 2 Â 10 6 B16 OVA/ILÀ10 tumor cells, only 3/12 (25%) mice immunized with the control CD8
þ T control cells were protected from tumor growth. In the mice immunized with the engineered CD8 þ T TNF cells, 10/12 (83% mice) were protected from tumor growth (Po0.05), indicating that the long-term antitumor immunity induced by adoptive transfer of engineered CD8
þ T TNF cells is significantly stronger than that of the control CD8 þ T control cells. In addition, the tumor-bearing mice with complete solid tumor regression after transfer of the engineered CD8 þ T TNF cells also showed a similar long-term antitumor protection as the Transgene TNF-a expression sustains engineered CD8 þ T-cell survival in vivo To investigate the role of TNF-a derived from the CD8 þ T cells and the host in transferred CD8
þ T-cell survival in vivo, we conducted another kinetic study by transferring CD8 þ T cells derived from OT I or OT I(TNF-a À/À ) mice to C57BL/6 mice or C57BL/6 mice with TNF-a gene KO. As shown in Figure 7a and b, the numbers of detected OVA-specific CD8 þ T cells in peripheral blood of C57BL/6 mice with DC OVA -activated CD8 þ T-and T(TNF-a À/À )-cell transfer accounted for around 12% of the total CD8 þ T-cell population at day 5 subsequent to adoptive transfer. The numbers of detected OVA-specific CD8 þ T cells became 8.2 and 1.2% in the peripheral blood of C57BL/6 mice with transfer of CD8 þ T cells at 12 and 30 or even 90 days subsequent to adoptive transfer (Figure 7a) . However, the numbers dramatically dropped to 0.5%, and then completely disappeared in the peripheral blood of C57BL/6 mice with transfer of CD8 þ T(TNF-a À/À ) cells at 12 and 30 or even 90 days subsequent to adoptive transfer (Figure 7a ), indicating that TNF-a derived from the donor CD8 þ T cells plays an important role in transferred donor CD8 þ T-cell survival in vivo. In addition, the number of detected OVAspecific CD8 þ T cells in peripheral blood of C57BL/6 mice with TNF-a gene KO were 10% of the total CD8 þ T-cell population at day 5 subsequent to adoptive transfer of DC OVA -activated CD8 þ T cells. However, the numbers also dramatically dropped to 0.2%, and then completely disappeared in the peripheral blood at 12 and 30 or even 90 days subsequent to adoptive T-cell transfer (Figure 7a ), indicating that TNF-a derived from the host also plays an important role in transferred donor CD8 þ T-cell survival in vivo.
Discussion
Retrovirus and adenovirus are commonly used for delivery of transgenes to cells or tissues. 39 Retroviruses integrate their genome into the host DNA of dividing cells, and this provides the possibility of long-term transgene expression. However, its random integration may cause insertional mutagenesis in the host cells. Recently it has been shown that retroviral vectors can cause leukemia formation. 40 Efficient infection of target cells by AdV requires two predominant viral-host cell receptor interactions. Primary adsorption of AdV relies on the interaction of the viral knob domain with a cellular surface receptor designated coxsackievirus and adenovirus receptor (CAR). 41 Subsequently, the interaction of RGD motifs on the viral penton base with the cellular aVb3 and aVb5 integrins facilitates AdV entry via 
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þ T-cell therapy Z Ye et al clathrin-mediated endocytosis. 42, 43 Although AdV can infect a wide range of cell types, lymphocytes and DCs are not generally susceptible to AdV infection, in part because of the absence of CAR expression 44, 45 Fiber-gene modification by insertion of RGD sequence in the viral fiber knob's H1 loop has been shown to enhance AdV infection of DC through binding of RGD motif to DC integrins leading to enhanced DC-mediated antitumor immunity. 46, 47 To enhance T-cell infection, we constructed a recombinant MF AdVTNF with fiber-gene modification and transfected CD8 þ T cells with MF AdVTNF. We found a fivefold increase of transgene human TNF-a secretion by CD8 þ T TNF cells transfected with the fiber gene-modified MF AdVTNF, compared to CD8 þ T cells transfected with the original AdVTNF without viral fiber modification. CTLs are able to lyse target cells by two mechanistically distinct, but functionally similar mechanisms:
48 an antigen-specific Ca 2 þ -dependent perforin/granzyme mechanism and an antigen-nonspecific Ca 2 þ -independent Fas/FasL mechanism. We showed that the engineered CD8 þ T TNF cells exhibited an upregulation of perforin and displayed stronger in vitro cytotoxicity to tumor cells than the control T control cells. We also demonstrated that the in vitro T TNF cell cytotoxicity is mainly mediated by perforin secretion, which is consistent with our previous reports. 33, 34 In this study, we also analyzed the therapeutic effect of engineered OVA-specific CD8 þ T TNF cells in mice bearing either 12-day lung micrometastasis or solid tumors (B5 mm in diameter) secreting IL-10. We showed that the engineered CD8 þ T TNF cells secreting the transgene-coded human TNF-a eradicated the IL-10-secreting B16 OVA/ILÀ10 lung metastasis in all 10/10 mice, whereas the control DC OVA -activated CD8 þ T (T control ) and DC OVA -activated CD8 þ T (T þ rTNF) cells with further culturing in the medium containing the recombinant human TNF-a eliminated lung metastasis in only 2/10 and 1/10 mice, respectively, indicating that the engineered CD8 þ T TNF cells have enhanced in vivo therapeutic effect on the IL-10-secreting B16 OVA/ILÀ10 lung metastasis. In mice bearing solid B16 OVA/ILÀ10 tumors, all 10/10 mice with treatment of the control CD8 þ T control cells died within 24 days after tumor cell challenge, whereas 6/10 mice with treatment of the engineered CD8
þ T TNF cells were free of tumors, confirming that the engineered T TNF cells have stronger in vivo therapeutic effect on the IL-10-secreting B16 OVA/ILÀ10 solid tumors than the control CD8 þ T control cells. To improve further the therapeutic effect, a combinational immunotherapy using the engineered CD8 þ T TNF cells and CD4 þ Th cells and/or the chemokine gene (lymphotactin and IP-10) therapy for enhancement of CD8 þ T-cell tumor infiltration 33, 49, 50 is underway in our laboratory to eradicate completely IL-10-secreting B16 OVA/ILÀ10 tumors (B5 mm in diameter and even larger in size). It has been reported that the mechanism of in vivo CD8 þ T-cell-mediated tumor regression is distinct from that of in vitro CD8 þ T-cell-mediated cytotoxicity, and is independent of perforin and FasL by using CD8 þ T cells with perforin gene knockout or FasL mutant 51, 52 Recently, Hollenbaugh et al. 53 demonstrated that CD8 þ T cell-secreted, but not the host-derived IFN-g play an important role in eradication of solid tumors by regulating CD8 þ T-cell expansion and migration and inducing tumor cell apoptosis. Blohm et al. 54 visualized adoptive CD8 þ T-cell-mediated tumor destruction and found that tumors 'melt' from the inside were derived from destruction of tumor vasculature and accumulation of granulocytes. The enhancement of in vivo therapeutic effect of the engineered T TNF cells observed in this study may not be due to its upregulated expression of perforin, but may be associated with its enhanced secretion of the transgenecoded human TNF-a as well as its elongated survival in vivo. TNF-a plays an essential role in CD8 þ T-cellmediated elimination of tumors in vivo 52, 55 possibly by its direct cytotoxicity to tumor cells leading apoptosis through engagement of the p55 TNF-a receptor I. 56 The inflammatory cytokine TNF-a also activates macrophages, natural killer cells and T cells 20, 57 by its binding to the p75 TNF-a receptor II (TNFRII). 55 In addition, it deactivate aVb3 integrin on angiogenic endothelial cells leading to lack of adhesion and apoptosis 58 and promoting intravascular thrombosis. 59 Recently, it has further been reported that TNF-a inhibits the suppressive function of regulatory T (Tr) cells by upregulated expression of TNFRII on Tr cells leading to downregulation of FoxP3 expression. 60 Therefore, in addition to the IFN-g secreted by engineered CD8 þ T cells, enhanced secretion of TNF-a by engineered CD8 þ T cells may (i) induce destruction of tumor vasculatures, (ii) activate immune cells, (iii) suppress Tr cells and (iv) directly induce tumor cell apoptosis, leading to enhancement of in vivo therapeutic effect of the engineered T TNF cells in this study.
The critical importance for a successful T-cell therapy is duration of in vivo persistence of the transferred CD8 þ T cells. 37 Unfortunately, in vitro cultured antigen-specific CD8 þ T cells, particularly CD8 þ T-cell clones, often die only a few hours after adoptive transfer and generally do not survive more than a matter of days, which greatly limits treatment efficacy. 61, 62 This is because the vast majority of activated CD8 þ T cells die by activationinduced cell death via apoptosis, and only a small portion of these T cells survives for extended periods. 63 In this study, we found that the number of detected OVA-specific CD8 þ T cells in peripheral blood of the mice with CD8 þ T TNF and CD8 þ T controlÀ cell transfer accounted for 18 and 12% of the total CD8 þ T-cell population at day 5 after adoptive transfer. However, the numbers gradually dropped to 14 and 9.3% at day 12, and 1.8 and 1.2% at day 30 subsequent to adoptive transfer, but stably maintained for at least 3 months thereafter, indicating that the engineered CD8 þ T TNF cells have prolonged survival in vivo, compared with the control CD8 þ T control cells. The importance of TNF-a in CD8 þ T-cell survival in vivo has been elucidated by using C57BL/6 and OT I mice with TNF-a gene KO. Our data showed that the number of detected OVA-specific CD8 þ T cells in TNF-a-gene engineered CD8 þ T-cell therapy Z Ye et al peripheral blood of C57BL/6 mice with CD8 þ T(TNFa À/À )-cell transfer or in peripheral blood of C57BL/ 6(TNF-a À/À ) mice with CD8 þ T-cell transfer all dramatically dropped to 0.5 and 0.2% of the total CD8 þ T-cell population and both completely disappeared at days 12 and 30 after transfer, respectively, indicating that both the donor's cellular and the host TNF-a are important in CD8 þ T-cell survival in vivo. Recently, it has been reported that membrane TNF-a can delay T-cell activation-induced cell death by activation of AKT and NF-kB, 64 which leads to elongated T-cell survival. Our results are thus consistent with a previous report by Dobrazanski, et al., 65 demonstrating that CD8 þ T-cell therapeutic effect was significantly less efficient in TNF-a À/À KO mice. These long-lived memory T cells possess the unique ability to respond rapidly and specifically to the antigen. 38 Our data showed that, after the boost, the expanded OVA-specific CD8 þ T cells accounted for 22 and 36% of the total CD8 þ T-cell population in the mice with previous transfer of the control CD8 þ T control and the engineered CD8
þ T TNF cells, respectively. Interestingly, our data also demonstrated that transfer of the engineered CD8 þ T TNF cells further leads to a stronger longterm antitumor immunity against the IL-10-secreting B16 OVA/ILÀ10 tumor cell challenge. Dobrazanski et al. 65 previously reported the induction of the host antigen-specific CD8
þ Tm cells in lung tissues after adoptive transfer of the donor antigen-specific CD8 þ effector T cells. However, the mechanism involved in this interesting finding was not elucidated. In this study, we also examined the origin of expanded OVAspecific CD8
þ Tm cells in C57BL/6.1 (CD45.1 þ ) mice with transfer of OVA-specific CD8 þ 45.2 þ T TNF cells using PE-tetramer, FITC-CD8 and ECD-CD45.1 or ECD-CD45.2 stainings. Our data demonstrated that a majority (B80%) of the expanded OVA-specific CD8 þ T cells were still CD45.2 positive, indicating that they are derived from the originally transferred donor CD8 þ T cells. Interestingly, we also found that around 20% of the expanded OVA-specific CD8 þ T cells were CD45.1 positive, indicating that they are derived from the CD45.1-positive host. We have recently demonstrated that DC-activated CD8 þ T cells acquired peptide/MHC I (pMHC I) complexes and costimulatory molecules from DC and acted as T-antigen presenting cell (T-APC) capable of stimulating the host central memory CD8 þ T-cell responses via acquired pMHC I and CD80 costimulation, and IL-2 secretion. 36 Therefore, the expanded CD45.1-positive CD8 þ T cells observed in this study should be derived from the donor's CD8 þ T TNF -cell-stimulated host central memory CD8
þ T-cell responses.
Taken together, our data show that the recombinant fiber-modified adenovirus MF AdVTNF has enhanced capacity to mediate T-cell transfection. The engineered CD8
þ T TNF cells with MF AdVTNF-mediated gene transfer secrete significant amount of transgene-coded TNF-a, exhibit enhanced cytotoxicity and elongated survival in vivo, eradicate immunosuppressive IL-10-secreting lung metastasis and solid tumors, and induce enhanced long-term antitumor immunity after adoptive transfer. Therefore, CD8
þ T cells engineered to secrete TNF-a may be useful when designing strategies for adoptive T-cell therapy of solid tumors.
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